About us

  • 메인

  • History

History

Growth

2026~

  • 2026.08
    Listed on the KOSDAQ Market of the Korea Exchange (KRX)
  • 2026.06
    Initiation of Global Phase 2a Clinical Trial for IGT-303 (Australia, New Zealand, South Korea)
  • 2026.03
    Initiated Phase 2b/3 Clinical Trial of IGT-427 (MK-8748) for NVAMD
  • 2026.02
    Announced Phase 2a Clinical Trial Results of IGT-427 (MK-8748)
Acceleration

2025
~ 2022

  • 2025.12
    Received AA Ratings in KOSDAQ Technology Assessment from e-Credible and NICE Information Service
  • 2025.11
    Initiated Phase 1/2a Clinical Trial of IGT-303 (Australia)
  • 2025.05
    Established the 3rd Scientific Advisory Boards
  • 2024.11
    Initiated Phase 1/2a Clinical Trial of IGT-427 (MK-8748) for nVAMD, DME, and BRVO
  • 2024.07
    Integrated IGT-427 into MSD's Core Pipeline (MK-8748) Following the Acquisition of EyeBio
  • 2024.07
    Series B Round
  • 2023.03
    Series A Round
  • 2022.10
    Executed an Out-licensing and Co-development Agreement for IGT-427 with EyeBio
Foundation

2021
~ 2018

  • 2021.12
    Bridge Round
  • 2021.05
    ~ 2021.12
    Established the 1st and 2nd Scientific Advisory Boards
  • 2020.09
    Seed Round
  • 2019.09
    Secured Exclusive Patent Rights from KAIST / IBS
  • 2018.03
    Incorporated INGENIA Therapeutics Inc. (Boston, USA)